Green Cross Medical Science Corporation
Green Cross Medical Science Corporation manufactures and sells diagnostic reagents and medical devices in South Korea and internationally. The company offers immunology diagnostic reagents. It also provides COVID-19 kit; blood glucose monitoring system; HbA1c test machine; and Gcare LIPID and LIPID printer. Green Cross Medical Science Corporation was founded in 1972 and is headquartered in Yongin… Read more
Green Cross Medical Science Corporation - Asset Resilience Ratio
Green Cross Medical Science Corporation (142280) has an Asset Resilience Ratio of 9.78% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Green Cross Medical Science Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Green Cross Medical Science Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩9.41 Billion | 9.78% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩9.41 Billion | 9.78% |
Asset Resilience Insights
- Limited Liquidity: Green Cross Medical Science Corporation maintains only 9.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Green Cross Medical Science Corporation Industry Peers by Asset Resilience Ratio
Compare Green Cross Medical Science Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Green Cross Medical Science Corporation (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Green Cross Medical Science Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | ₩0.00 | ₩90.53 Billion | -- |
| 2022-12-31 | 11.14% | ₩10.75 Billion | ₩96.47 Billion | +9.22pp |
| 2021-12-31 | 1.92% | ₩1.84 Billion | ₩95.63 Billion | -2.34pp |
| 2020-12-31 | 4.26% | ₩4.50 Billion | ₩105.60 Billion | -11.14pp |
| 2019-12-31 | 15.40% | ₩13.68 Billion | ₩88.87 Billion | +1.40pp |
| 2018-12-31 | 13.99% | ₩8.95 Billion | ₩63.97 Billion | +8.04pp |
| 2017-12-31 | 5.95% | ₩3.60 Billion | ₩60.54 Billion | +2.10pp |
| 2016-12-31 | 3.85% | ₩2.45 Billion | ₩63.61 Billion | -- |